Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database

J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2406-2408.e1. doi: 10.1016/j.jaip.2020.03.015. Epub 2020 Mar 31.

Authors

Marion Lepelley¹, Charles Khouri², Clémence Lacroix³, Laurence Bouillet⁴

Affiliations

¹ Centre régional de pharmacovigilance, CHU Grenoble-Alpes, Grenoble, France. Electronic address: mlepelley@chu-grenoble.fr.
² Centre régional de pharmacovigilance, CHU Grenoble-Alpes, Grenoble, France.
³ Centre régional de pharmacovigilance, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
⁴ Médecine interne, Centre national de référence des angioedèmes bradykiniques, CHU Grenoble-Alpes, Grenoble, France.

PMID: 32244025
DOI: 10.1016/j.jaip.2020.03.015

No abstract available

MeSH terms

Angioedema* / chemically induced
Angioedema* / epidemiology
Angiotensins
Dipeptidyl-Peptidase IV Inhibitors* / adverse effects
Humans
Pharmacovigilance
World Health Organization

Substances

Angiotensins
Dipeptidyl-Peptidase IV Inhibitors